159 related articles for article (PubMed ID: 37575222)
1. Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab.
Ye W; Cai L; Zhang M; Wu Y; Sun H; Wang YD; Xia Y
Front Immunol; 2023; 14():1221418. PubMed ID: 37575222
[TBL] [Abstract][Full Text] [Related]
2. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
3. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
Chen Z; Lu X; Koral K
Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
[TBL] [Abstract][Full Text] [Related]
4. Camrelizumab: an investigational agent for hepatocellular carcinoma.
Xu B; Sun HC
Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
[TBL] [Abstract][Full Text] [Related]
5. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
Qin S; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Chen C; Zou J
Lancet Oncol; 2020 Apr; 21(4):571-580. PubMed ID: 32112738
[TBL] [Abstract][Full Text] [Related]
6. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
7. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
8. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial.
Li JX; Su TS; Gong WF; Zhong JH; Yan LY; Zhang J; Li LQ; He ML; Zhang RJ; Du YQ; Wang XT; Liang SX; Xiang BD
Hepatol Int; 2022 Oct; 16(5):1179-1187. PubMed ID: 36001228
[TBL] [Abstract][Full Text] [Related]
9. TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports.
Xin H; Zhang C; Ding Z; Zhang M; Ding G; Li N
Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101777. PubMed ID: 34333197
[No Abstract] [Full Text] [Related]
10. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-related pneumonitis induced by camrelizumab: a case report and review of literature.
Li L; Lou A; Yu J
Ann Palliat Med; 2021 Jul; 10(7):8460-8466. PubMed ID: 34044548
[TBL] [Abstract][Full Text] [Related]
12. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
[TBL] [Abstract][Full Text] [Related]
13. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.
Zhang C; Wang G; Liu N; Li T; Zhu J; Hou H
Front Immunol; 2024; 15():1387465. PubMed ID: 38646529
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial.
Xia Y; Tang W; Qian X; Li X; Cheng F; Wang K; Zhang F; Zhang C; Li D; Song J; Zhang H; Zhao J; Yao A; Wu X; Wu C; Ji G; Liu X; Zhu F; Qin L; Xiao X; Deng Z; Kong X; Li S; Yu Y; Xi W; Deng W; Qi C; Liu H; Pu L; Wang P; Wang X
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379737
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
16. bMSAF is a prognostic predictor for advanced hepatocellular carcinoma patients treated with immune checkpoint inhibitor camrelizumab and anti-angiogenic agent apatinib combination therapy.
Xu G; Cui L; Li J; Wang Q; Li P; Xia X; Yi X; Guan Q; Xu J
Clin Transl Med; 2022 Oct; 12(10):e1086. PubMed ID: 36245284
[No Abstract] [Full Text] [Related]
17. Camrelizumab: First Global Approval.
Markham A; Keam SJ
Drugs; 2019 Aug; 79(12):1355-1361. PubMed ID: 31313098
[TBL] [Abstract][Full Text] [Related]
18. A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report.
Chen Y; Zhang H; Shi J; Wang T
Onco Targets Ther; 2020; 13():12471-12476. PubMed ID: 33299330
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment.
Wang D; Zhang S; Ding P; Zhao Y; Zhang X; Zhao Q
Iran J Immunol; 2020 Jun; 17(2):167-171. PubMed ID: 32602470
[TBL] [Abstract][Full Text] [Related]
20. Predicting Outcome in Combination Treatment of TACE and Camrelizumab for Advanced Hepatocellular carcinoma: Tumor Hypervascularity and Reactive Cutaneous Capillary Endothelial Proliferation.
Yin L; Liu KC; Lv WF; Xu SB; Lu D; Zhou CZ; Cheng DL; Gao ZG; Shi CS; Su MX
Drug Des Devel Ther; 2022; 16():3421-3429. PubMed ID: 36203820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]